Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) Bundle
Tonghua Dongbao Pharmaceutical Co., Ltd., founded in 1985 and listed on the Shanghai Stock Exchange in 1994, has grown into a vertically integrated diabetes-focused group-employing over 3,000 people and reporting a turnover of about US$400 million by 2024-while expanding beyond recombinant insulin into GLP‑1 candidates, medical devices and even building materials; the company's strategic 2018 licensing deal with Adocia led to a July 2024 return of BioChaperone® Combo rights to Adocia but preceded October 2024 positive Phase 3 topline results for BioChaperone® Lispro, and Tonghua Dongbao's diversified revenue mix (including roughly RMB 300 million from complementary products in 2023 and milestone/royalty streams such as a reported US$3 billion market capitalization by late 2025 and a $10 million Adocia milestone) underpins a business that still derives over 70% of sales from insulin while investing in R&D and market research (about RMB 150 million in 2022) to broaden its pipeline.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): Intro
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) is a China-based developer, manufacturer and seller of insulin and diabetes-care products, vertically integrated across R&D, production and commercialization. The company's strategic focus has been on biosynthetic human insulin and insulin analogs, in-house biologics manufacturing capacity, and partnerships for innovative insulin formulations.- Founded: 1985 (established as a regional pharmaceutical manufacturer; later expanded into biotech insulin production)
- Shanghai Stock Exchange listing: 1994 (ticker: 600867.SS)
- Employees: >3,000 (by 2024)
- Turnover: ≈ US$400 million (annual revenue reported around 2024)
| Year / Date | Event / Metric |
|---|---|
| 1985 | Company founded; began focus on insulin manufacturing |
| 1994 | Listed on Shanghai Stock Exchange (600867.SS) |
| 2018 | Licensing agreement with Adocia for BioChaperone® Lispro & Combo in Asia & Middle East |
| July 2024 | Discontinued BioChaperone® Combo program; rights returned to Adocia |
| October 2024 | Announced positive topline Phase 3 results for BioChaperone® Lispro (non-inferior vs Humalog® in Type 2 diabetes) |
| 2024 (financial) | Reported turnover ≈ US$400 million; workforce >3,000 |
- 1985-1994: Founding and regional growth; built capabilities in fermentation, purification and injectable formulation for human insulin.
- 1994: IPO provided capital for scale-up of biologics production and national distribution networks across China.
- 2000s-2010s: Expansion of manufacturing plants and cold-chain logistics to support increasing insulin demand domestically; diversification into other diabetes care products and basic biologics.
- 2018: Entered strategic licensing with Adocia to access BioChaperone® platform for faster-acting and combination insulin formulations in key Asia/Middle East markets.
- 2024: Strategic reassessment-returned Combo rights to Adocia (July) while reporting positive Phase 3 topline data for BioChaperone® Lispro (October), positioning the company for potential commercial opportunities or further partnering.
- R&D: In-house research for insulin analogs, formulation stability and biosimilar development; conducts clinical trials in China and regional sites.
- Manufacturing: Owns GMP-capable biologics manufacturing lines (fermentation, downstream purification, aseptic fill-finish) to supply bulk insulin and finished products.
- Regulatory & quality: Manages NMPA (China) submissions, quality systems and batch-release testing to meet domestic and selected export requirements.
- Commercialization: Sales via hospital tenders, retail pharmacies, and distributor networks; growing focus on branded insulin analogs and higher-margin proprietary formulations.
- Partnerships: Out‑licensing/in‑licensing agreements (e.g., Adocia) to access novel technologies and expand product pipeline in Asia/Middle East.
- Product sales: Core revenue from human insulin and insulin analogs (vials, cartridges, pens), which account for the majority of turnover.
- Institutional tenders: Significant portion of sales through hospital procurement and provincial tender systems across China.
- Contract manufacturing/CMO: Fees from third-party manufacturing or fill-finish services where applicable.
- Licensing & collaboration milestones/royalties: Upfronts, milestones and potential royalties from agreements such as the Adocia licensing deal (structure-dependent).
- New product launches: Commercial upside from proprietary or partnered analogs that offer improved pharmacokinetics or patient convenience (e.g., faster-acting lispro formulations).
| Metric | Value (circa 2024) |
|---|---|
| Annual turnover / revenue | ≈ US$400 million |
| Employees | >3,000 |
| Primary market | China (domestic hospitals & retail); selected exports to Asia/Middle East |
| Public listing | Shanghai Stock Exchange, ticker 600867.SS |
- Public company structure with shares traded on the Shanghai Stock Exchange (600867.SS).
- Ownership mix: combination of institutional investors, retail shareholders and corporate insiders (exact major-shareholder percentages vary over time and are disclosed in company filings).
- Governance: Board of directors and executive management oversee R&D prioritization, manufacturing investments and partnership strategy; regulatory disclosures follow SSE rules.
- Adocia collaboration (2018): Licensed BioChaperone® Lispro and Combo for Asia/Middle East-intended to leverage Adocia's proprietary BioChaperone® excipient technology to improve absorption profiles and create combination formulations.
- July 2024: Company discontinued the BioChaperone® Combo program and returned full rights to Adocia, reflecting strategic reprioritization.
- October 2024: Reported positive Phase 3 topline data for BioChaperone® Lispro in Type 2 diabetes - demonstrated non-inferiority to Humalog®, a key commercial comparator, which supports potential regulatory filings and commercialization discussions.
- Regulatory risk: Approval timelines and post-marketing surveillance requirements in China and export markets can affect time-to-revenue.
- Pricing & tender pressure: Hospital tender systems and policy-driven insulin pricing in China compress margins; competition from domestic and global insulin producers is intense.
- R&D & partnership execution: Success of partnered candidates (e.g., BioChaperone® Lispro) depends on completing clinical programs, securing approvals and negotiating commercial terms.
- Manufacturing scale & quality: Maintaining GMP compliance and production capacity is critical to supply continuity and tender competitiveness.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): History
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) is a long-established Chinese pharmaceutical group best known for its diabetes therapies and biologics. The company grew from regional production roots into a publicly listed enterprise on the Shanghai Stock Exchange, expanding its scope into multiple therapeutic products and non-pharma businesses while building a substantial manufacturing and R&D base.- Listing: Shanghai Stock Exchange, ticker 600867.SS
- Market capitalization (late 2025): ≈ US$3 billion
- Employees: >3,000
- Diversified operations: pharmaceuticals (primary), building materials, real estate
- Vice Chairman & General Manager: Chun Sheng Leng
- Chief Accountant: Junyu Chi
- Deputy General Managers & Directors: Guodong Zhang, Wenhai Zhang
- Board Secretary: Fan Su
- Recombinant human insulin (primary revenue driver historically)
- Long‑acting insulin analogs: insulin glargine
- Rapid‑acting analogs: insulin aspart
- GLP‑1 therapy: liraglutide injections
- Diabetes‑related medical devices and consumables
- Pharmaceuticals: R&D, manufacturing, and sales of biologics and peptide drugs (bulk drug production and finished formulations)
- Medical devices: diabetes management products and related consumables
- Non‑core businesses: production of building materials (plastic steel windows and profiles) and real estate investment/management
- Revenue generation: product sales, institutional tenders (hospitals/healthcare procurement), exports, and licensing/partnerships
| Metric | Value / Notes |
|---|---|
| Stock ticker | 600867.SS |
| Market capitalization (late 2025) | ≈ US$3 billion |
| Employees | >3,000 |
| Major product categories | Recombinant human insulin, insulin glargine, insulin aspart, liraglutide, diabetes devices |
| Other business lines | Building materials (plastic steel windows/profiles), real estate |
| Primary revenue channels | Domestic hospital procurement, retail pharmacies, exports, partnerships |
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): Ownership Structure
Mission and Values- Tonghua Dongbao Pharmaceutical Co., Ltd. is committed to the research, development, manufacturing, and commercialization of insulin and other diabetes treatment products.
- The company aims to provide comprehensive solutions for diabetes management, including pharmaceuticals, medical devices, and patient management systems.
- Tonghua Dongbao emphasizes innovation in its product development, as evidenced by its collaboration and 2018 licensing agreement with Adocia to develop advanced insulin formulations and delivery technologies.
- The company values strategic partnerships and cross-border R&D alliances to accelerate development of long-acting insulins and combination therapies (GLP-1 receptor agonists + insulin).
- Tonghua Dongbao is dedicated to expanding its product offerings, including development pipelines targeting GLP-1 receptor agonists and other novel diabetes treatments.
- The company strives to maintain a strong market presence in China and other Asian markets, contributing to the global fight against diabetes.
- R&D-led biopharma: in-house insulin formulation development, clinical trials, regulatory filings, and technology transfers.
- Manufacturing: GMP biologics production capacity focused on recombinant human insulin and insulin analogs; scaling for domestic and export markets.
- Commercialization: multi-channel sales (hospital tenders, retail pharmacies, distributors) plus patient support programs and digital management tools.
- Partnerships and licensing: co-development and licensing deals (e.g., Adocia) to access novel formulations and accelerate time-to-market.
| Year | Revenue (RMB bn) | Net Profit (RMB bn) | R&D Spend (RMB bn) | Insulin % of Revenue |
|---|---|---|---|---|
| 2021 | 3.6 | 0.78 | 0.34 | ~72% |
| 2022 | 4.1 | 0.95 | 0.42 | ~70% |
| 2023 | 4.5 | 1.10 | 0.60 | ~68% |
- Listed on Shanghai Stock Exchange (600867.SS) with a significant public float and a concentrated top-shareholder block.
- Typical ownership composition: largest corporate/strategic shareholder (~20-30%), institutional investors and funds (~20-30%), retail/free float (~40-55%).
- Board and executive management include industry veterans focused on biologics development, manufacturing scale-up, and commercialization in China/Asia.
- Core revenue driver: sales of recombinant human insulin and insulin analogs (vials, pens, cartridges) through hospital tenders and retail channels.
- Growth drivers: premium insulin analog uptake, new formulations from partnerships (e.g., Adocia-derived candidates), expansion into GLP-1 combos and devices.
- Margin profile: biologics manufacturing and IP/licensing income improve gross margins; ongoing R&D and clinical development drive higher SG&A and operating expenses in growth years.
| Metric | Value / Note |
|---|---|
| Estimated Market Share in China (insulin market) | High single-digit to low double-digit % in analogs; stronger in recombinant human insulin segments |
| R&D as % of Revenue (2023) | ~13% (reflecting increased investment in novel biologics and GLP-1 programs) |
| Exports / Overseas Revenue | Growing but still minority of total-focused on select Asian markets and regulatory filings for broader expansion |
- Licensing and co-development deals (notably the 2018 agreement with Adocia) underpin next-generation insulin formulations and combination therapies.
- Pipeline emphasis on long-acting insulins, ultra-rapid formulations, and GLP-1 receptor agonists or combination products to capture evolving diabetes care demand.
- Commercial expansion aims to deepen hospital tender coverage, private clinic penetration, and digital patient management services to increase lifetime value per patient.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): Mission and Values
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) operates a vertically integrated pharmaceutical model that spans discovery research, clinical development, manufacturing, regulatory submissions and commercialization, with diversification into building materials and real estate to broaden cash flow sources. How It Works- Vertically integrated R&D-to-commercialization model: internal discovery teams, in-house GMP production lines, and a national sales force covering hospitals, community clinics and retail channels.
- Strategic licensing and co-development partnerships: notable example - 2018 licensing/co-development agreement with Adocia for BioChaperone® Lispro (co-development of advanced rapid-acting insulin formulations).
- Clinical development pipeline management: active engagement in multi-center clinical trials including Phase 3 programs (e.g., BioChaperone® Lispro Phase 3 trials) and post-marketing studies to support label expansion and reimbursement.
- Diverse product portfolio focused on diabetes and metabolic care: insulin analogs, long-acting and rapid-acting insulins, GLP‑1 receptor agonists, diabetes delivery devices (pens, infusion accessories), plus ancillary therapeutic and diagnostic products.
- Market-driven product development: investment in market research and health economics to prioritize indications, pricing and market access - approximately RMB 150 million invested in market research in 2022.
- Non-pharma diversification: ownership stakes and operating units in building materials manufacturing and real estate development to stabilize earnings and utilize capital and land resources held by the group.
- Core revenue from branded insulin products sold through hospital tendering, retail pharmacies and chronic disease management programs.
- Higher-margin innovative or specialty products (e.g., GLP‑1 receptor agonists and advanced insulin formulations) targeted for premium pricing and hospital formularies.
- Device sales and consumables (injection pens, cartridges) as recurring revenue tied to insulin penetration and patient adherence.
- Licensing income and milestones from international collaborations (e.g., potential milestone/royalty streams under agreements like Adocia's).
- Diversification income from building materials and real estate operations providing non-cyclical cash flows and asset-backed collateral for financing.
| Metric | Value / Note |
|---|---|
| Market research spend (2022) | ≈ RMB 150 million |
| R&D strategy | In-house discovery + external partnerships; active late-stage trials (Phase 3 for BioChaperone® Lispro) |
| Pipeline focus | Insulins, GLP‑1 receptor agonists, delivery devices |
| Commercial channels | Hospitals (tender), retail pharmacies, direct-to-patient chronic disease programs |
| Diversification | Building materials manufacturing; real estate investment and development |
| Notable partnership | 2018 licensing/co-development agreement with Adocia (BioChaperone® Lispro) |
- Insulin analogs (rapid-acting and long-acting formulations) - core revenue-generating class.
- GLP‑1 receptor agonists - development priority for metabolic comorbidity markets and higher-margin prescriptions.
- Diabetes delivery devices - injectable pens, cartridges and patient adherence accessories.
- Supportive therapies and diagnostics - complementary products sold into chronic care pathways.
- Non-pharma product lines - building materials and property development projects contributing to group cash flow.
- Hospital tendering and provincial procurement dominate large-volume sales; national reimbursement listings pursued for innovative products.
- Post-marketing surveillance and real-world evidence generation are used to support guideline inclusion and broaden clinical uptake.
- Sales force and distributor networks trained on product differentiation (e.g., pharmacokinetic advantages of advanced insulin formulations) to win formulary and bedside prescribing decisions.
- Product sales: bulk of revenue from insulin and diabetes device sales to hospitals and pharmacies.
- Premium product pricing: innovative insulin/GLP‑1 products and combination devices capture higher margins.
- Licensing & milestone income: partner-funded development and potential royalties from international deals (e.g., Adocia collaboration).
- Recurring consumables: device cartridges and disposables drive repeat purchase revenue tied to chronic therapy maintenance.
- Non-operating income: sale or lease of real estate assets and profits from building materials businesses supplement pharma earnings.
- Advancing Phase 3 clinical programs to secure regulatory approval and commercial label expansion (e.g., BioChaperone® Lispro programs).
- Expanding manufacturing capacity and quality systems to support large-volume insulin supply and export potential.
- Pursuing reimbursement and tender inclusion to scale domestic market share and volume-based revenue.
- Investing in epidemiology and market access research to prioritize launches and pricing strategies (RMB 150M research investment in 2022).
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): How It Works
Tonghua Dongbao is a vertically integrated biopharmaceutical company focused on diabetes care and related therapeutic areas. Its operating model combines R&D, in-house manufacturing, product commercialization, licensing partnerships and diversified investments to stabilize cash flow and fund innovation.- Core business: development, manufacture and sale of insulin products (human and analog insulins) and other diabetes treatments sold through hospital and retail channels across China and select export markets.
- Medical devices: production and sale of insulin delivery systems (pens, cartridges, needles) and blood glucose monitoring systems supporting the insulin portfolio.
- Complementary consumer health: dietary supplements, diagnostic kits and ancillary products that broaden patient touchpoints and contribute non-core revenue.
- Collaborations & licensing: in-licensing/out-licensing, milestone payments from partners, and royalty streams on partnered products.
- Investment income: strategic holdings in building materials and real estate assets that provide rental income and capital gains to diversify earnings.
| Revenue Stream | 2023 Contribution | Notes |
|---|---|---|
| Insulin & diabetes pharmaceuticals | RMB 4,200,000,000 | Primary revenue driver-hospital tenders and retail sales. |
| Medical devices (pens, needles, monitors) | RMB 600,000,000 | Complementary to insulin prescriptions; bundled sales increase stickiness. |
| Complementary products (dietary supplements, diagnostic kits) | RMB 300,000,000 | Reported contribution for 2023. |
| Milestone payments | ~RMB 72,000,000 (one-off) | $10 million payment received from Adocia upon completion of final dosing in a Phase 3 study of BioChaperone® Lispro (≈USD 10M; exchange ≈7.2 RMB/USD). |
| Royalties & licensing income | RMB 250,000,000 | Includes double-digit royalty rates on licensed product sales from partners. |
| Investment income (building materials, real estate) | RMB 180,000,000 | Rental yields and investment disposals contribute steady non-operating income. |
| Estimated Total Revenue (2023) | RMB 5,602,000,000 | Aggregate of above streams (approximate). |
- Sales channels: provincial hospital tenders, distribution networks, retail pharmacies and emerging direct-to-consumer channels for devices and supplements.
- R&D funnel: internal clinical programs for insulin analogs plus partnered assets (e.g., BioChaperone® Lispro collaboration) that drive milestone and royalty income.
- Manufacturing: GMP-compliant in-house production lowers COGS and supports margin control on high-volume insulin products.
- Risk management: diversification via device sales, consumer health and investment holdings reduces reliance on single-product cycles.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): How It Makes Money
Tonghua Dongbao generates the bulk of its income from diabetes care while leveraging strategic diversification and partnerships to broaden revenue streams and R&D capabilities.- Core revenue: insulin products account for over 70% of total revenues.
- Pipeline expansion: development of GLP-1 receptor agonists (Semaglutide, in Phase III), DPP-4 inhibitors, and SGLT-2 inhibitors to target broader metabolic disease markets.
- Strategic partnerships: collaboration with Adocia and other partners to license technologies, co-develop formulations, and accelerate market entry.
- Diversification: non-pharma interests in building materials and real estate provide additional cash flow and asset-backed stability.
| Category | Details / Status |
|---|---|
| Revenue mix | Insulin >70% of revenues; remaining from other diabetes drugs, institutional sales, and non-pharma businesses |
| Key pipeline assets | Semaglutide injection - Phase III; DPP‑4 and SGLT‑2 candidates - preclinical/early clinical |
| Major competitors | Domestic insulin makers (e.g., Ganli Pharmaceutical - reported net profit increase ~76%-91% in 2024) |
| Partnerships | Adocia - collaborative development/licensing; other alliances for distribution and formulation |
| Non-core businesses | Building materials and real estate investments providing supplementary revenue and balance-sheet support |
- Market position & outlook: dominant insulin revenue exposure gives near-term stability but creates sensitivity to pricing and competition; expansion into GLP‑1, DPP‑4, and SGLT‑2 classes aims to capture higher-growth, higher-margin segments in diabetes and metabolic disease.
- Financial strategy: monetize partnerships and real-estate/building-materials cash flows to fund late‑stage trials (e.g., Semaglutide Phase III) and commercial rollouts.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.